PSNL

Personalis, Inc.
CAPPED RATING

Personalis, Inc. is a leader in population sequencing and cancer genomics, with a focus on data, scale, efficiency and quality. Personalis operates one of the largest sequencing operations globally and is currently the sole sequencing provider to the VA MVP. In oncology, Personalis is transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient\'s cancer and immune response. The Personalis® ImmunoID NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The PersonalisClinical Laboratory is GxP-aligned as well as CLIA\'88-certified and CAP-accredited.

Personalis, Inc. (PSNL) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (A); its weakest is Revisions (F). The rating has held at C for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.4 / 5.0
C
Value
B-
Factor Score 2.9 / 5.0
Growth
B-
Factor Score 3.0 / 5.0
Profitability
C-
Factor Score 2.0 / 5.0
Momentum
A
Factor Score 4.2 / 5.0
Revisions
F
Factor Score 0.0 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -16.0
EV / EBITDA -13.3
Rev Growth YoY 76.6%
Gross Margin 16.7%
Price Return 3M 13.1%
Price Return 12M 96.1%
Catalyst Signal 0.00
Market Cap $1.7B
TTM Revenue $80.8M
Price / Sales 21.1
ROE -62.1%

Historical Factor Score Progression

Held C for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 B- (2.9) B- (3.0) C- (2.0) A (4.2) F (0.0) C (2.4)
2026-11-07 B- (2.9) C+ (2.7) C- (2.0) A- (4.0) F (0.0) C (2.3)
2026-10-31 B- (2.9) C+ (2.6) C- (2.0) A (4.3) F (0.0) C (2.4)
2026-10-24 B- (2.9) C+ (2.6) C- (2.0) A (4.4) F (0.0) C (2.4)
2026-10-17 B- (2.9) C+ (2.7) C- (2.0) A- (4.1) F (0.0) C (2.3)
Page 1 of 5